Biological E India s next Serum, Bharat Biotech of COVID-19 vaccine
The acquisition of Akorn India helped Biological E create a potential overall manufacturing capacity of over 1 billion doses per annum.
PB Jayakumar | June 2, 2021 | Updated 23:07 IST
Providence will provide necessary technology transfer for Biological E to manufacture mRNA vaccines in India.
The oldest Indian private vaccine maker, Hyderabad-based Biological E Limited, is emerging as a domestic powerhouse of COVID-19 vaccine manufacturing following its latest deal with Canada-based biotech company Providence Therapeutics.
In addition to the Providence deal, Biological E currently has a couple of in-house COVID-19 vaccines under development and another major manufacturing contract agreement for Johnson & Johnson s single-dose COVID-19 vaccine. It was among the earliest Indian companies to tap potential COVID-19 vaccine opportunities.